Skip to main content
. 2021 Sep 17;3(5):803–805. doi: 10.34067/KID.0003902021

Figure 1.

Figure 1.

Recommended measures to potentially decrease the risk of recurrent AKI from immune-related adverse events on rechallenge with immune checkpoint inhibitors. irAE, immune-related adverse events; PD1, programmed cell death protein 1; PD-L1, programmed death ligand 1; AIN, acute interstitial nephritis.